RxDoctor Payments Data

Thanh-Mai Vo, MD

Nephrology · Bridgeton, MONPI 1235367160

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 87.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $2,513 and has fallen 93.5% since, to $163 in 2025.

$5,033in general payments, 2019–2025

Across 59 payments — averaging $85.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Mallinckrodt Hospital Products Inc.$155
  • Venturemed Group, Inc.$141
  • Aurinia Pharma U.S., Inc.$90
  • Gilead$87
  • AstraZeneca$75
  • plus $92 from 5 others

What the payments were for

  • Travel & lodging$2,67453%
  • Food & beverage$2,25945%
  • Education$1002%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,033 in reported general payments places this provider in the 80th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$34,074
Medicare patients
128
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate11$21,024
Potassium Chloride14$454
Calcitriol36$274
Doxazosin Mesylate36$219
Nifedipine ErNifedipine21$140
Metoprolol Succinate18$129
Furosemide43$116
Amlodipine Besylate34$109
Losartan Potassium38$97
Tamsulosin Hcl14$80
Carvedilol12$41
Spironolactone26$41
Lisinopril12$26
Allopurinol12$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$75$21,02411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 nephrology providers in Missouri.

Other nephrology in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →